Brenntag AG (0MPT)
London Exchange · UK · prices in EUR · close of 19 Oct 2026
Key indicators
| Last close | EUR 64.02 |
|---|---|
| 52-week range | 42.41 – 66.66 |
| Return, 1 month / 3 months | +7.0% / +10.9% |
| Return, 1 year / 3 years | +32.2% / +1.5% |
| Trend | Uptrend |
| RSI (14) | 63 |
| Volatility (1 year) | 29.2% |
| Worst drawdown (1 year) | -24.5% |
| Average daily value traded | 3.86M EUR |
| Dividend yield | 3.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Brenntag is a chemical and ingredient distributor based in Germany. It connects producers of chemicals and ingredients with companies that use them, handling logistics, storage, mixing and related services. Its customers span industries such as pharmaceuticals, food, personal care, coatings, water treatment and industrial manufacturing, and it serves both large manufacturers and smaller regional businesses. The company operates through divisions focused on essential chemicals and on specialty ingredients, and it runs a broad distribution network across many countries.
On this site Brenntag AG appears as a stock on the London Exchange (UK), code 0MPT, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Brenntag AG (0MPT) trades on the London Exchange in UK. It last closed at EUR 64.02 on 19 October 2026.
Its price-based Market X-Ray is 70 out of 100 (a fair price profile), ranking 516 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 32.2% and over the last three months it rose 10.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 83 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 13.9% | ||
| From 52-week high | -1.6% | ||
| Momentum | 72 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 10.9% | ||
| 6-month return | 8.8% | ||
| 12-month return, skipping the last month | 23.6% | ||
| Risk (lower is better) | 63 · Fair | Typical risk for this exchange. | |
| Volatility (1 year) | 29.2% | ||
| Worst drawdown (1 year) | -24.5% | ||
| Liquidity | 65 · Fair | Moderate trading activity. | |
| Average daily value traded | 3.86M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 56 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 3.0% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +3.5% |
|---|---|
| 1 month | +7.0% |
| 3 months | +10.9% |
| 6 months | +8.8% |
| 1 year | +32.2% |
| 3 years | +1.5% |
| 5 years | −12.4% |
Signals
| 50-day / 200-day average | 61.15 / 56.21 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.29 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 21 May 2026 | EUR 1.9000 |
| 23 May 2025 | EUR 2.1000 |
| 24 May 2024 | EUR 0.3600 |
| 16 Jun 2023 | EUR 1.3900 |
| 10 Jun 2022 | EUR 1.4500 |
| 11 Jun 2021 | EUR 1.3500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.